(Q35964407)

11 August 2017

1 reference

title

Dose density in adjuvant chemotherapy for breast cancer (English)

1 reference

11 August 2017

1 reference

Marc L Citron

1

1 reference

11 August 2017

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

22

1 reference

11 August 2017

555-568

1 reference

11 August 2017

4

1 reference

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

11 August 2017

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Dose-dense anthracycline-based chemotherapy for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAK

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Docetaxel in the treatment of breast cancer: an update on recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200027134

21 January 2018

Identifiers

DOI

10.1081/CNV-200027134

1 reference

11 August 2017

1 reference

PubMed ID

15565814